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COLUMBINE PROFILE 
2FUNDS: 1984 - $34 MILLION 
1989 - $44 MILLION 
• 4GENERALPARTNERS 
• 44 LIMITED PARTNERS 
• 3 OFFICES: DENVER(2) 
PHOENIX (1) 
HOUSTON (1) 
• PORTFOLIO OF 37 INVESTMENTS 
• INVESTMENT STRATEGY: 
SEED AND START-UP 
TECHNOLOGY-DRIVEN 
WEST/SOUTHWEST BASED 
------------------ COLUMBINE VENTURE FUNDS 
I 
COLUMBINEJINVERSITY-SOURCED START-UPS 
COMPANY UNIVERSITY BUSINESS OUTCOME 
AFFERON ARIZONA/NIH NERVE ACTIVE 
DESENSITIZATION 
AGRIPRO NEV ADA (Reno) HYBRID PLANTS ACQUIRED 
ALBION UTAH ANESTIIESIA GAS ACQUIRED 
MEASUREMENT 
ANESTA UTAH DRUG DELIVERY ACTIVE 
BIEX CALIFORNIA- HORMONE DETECTION ACTIVE 
DAVIS 
CARDIOPULMONICS UTAH ARTIFICIAL LUNG PUBLIC 
COLLAGENEX SUNY PERIODONTITIS DRUGS ACTIVE 
HEPA TIX BAYLOR ARTIFICIAL LIVER ACTIVE 
-------------------- COLUMBINE VENTURE FUNDS 
J 
COLUMBINE UNIVERSITY-SOURCED STARTUPS (Cont'd.) 
COMPANY UNIVERSITY BUSINESS OUTCOME 
KRY SALIS NEW MEXICO NON-VOLATILE CHIP FAILED 
NANO PHASE ARGONNE NANO-MA1ERIALS ACTIVE 
NAT'L.LABS 
NE OGEN MICHIGAN ST. ANIMAL/PLANT HEALTH PUBLIC 
ORTHOLOGIC MONTANA ST. BONE & TISSUE HEALING PUBLIC 
PARADIGM TEXAS-AUSTIN ELECTRONICS ACTIVE 
RECEPTOR LABS ILLINOIS PEPTIDE DRUG DESIGN ACTIVE 
RHO DON MD ANDERSON CANCER DEJECTION ACTIVE 
' TOPONIETRIX CALIBCH SCANNING TUNNELING ACTIVE 
MICROSCOPY 
TSA UTAH STAIB DRUG ANALYSIS FAILED 
~~~~~~~~~~~~~~~~~~~~COLUMBINE VENTURE FUNDS 
CONCLUSIONS FROM COLUMBINE'S UNIV. SOURCED TECHNOLOGY 
• MOST ARE MEDICAL RELATED: 
MEDICAL 10 
AGRICULTURAL - 2 
INSTRUMENTS - 2 
ELECTRONICS - 2 
MATERIALS 1 
• SOURCES ARE DIVERSE 
14 DIFFERENT INSTITUTIONS 
VERY FEW OPPORTUNITIES MERIT START-UPS 
• SUCCESS RATE 
3 PUBLIC 
2ACQUIRED 
lOACTIVE 
2FAILED 
~~~~~~~~~~~~~~~~~~COLUMBINE VENTURE FUNDS 
IS IT A PRODUCT OR A BUSINESS? 
• MOST OPPORTUNITIES ARE PRODUCTS WHICH SHOULD BE 
LICENSED TO EXISTING COMPANIES 
• SOME SIMPLE TESTS FOR A TECHNOLOGY WHICH COULD BE BASIS 
FOR A START-UP: 
1. MARKET SIZE 
AT LEAST $100 MILLION/YR 
BASIS FOR $30 MILLION/YR REVENUES IN 5 YEARS 
2. STRONG PROPRIETARY POSITION 
3. A BASIC TECHNOLOGY CAPABLE OF DEVELOPING A 
PIPELINE OF PRODUCTS 
4. KNOWLEDGEABLE FOUNDERS - REASONABLE TO DEAL WITH 
5. INVESTMENT/LICENSE AVAILABLE ON REASONABLE TERMS 
------------------ COLUMBINE VENTURE FUNDS 
VENTURE CAPITALIST OBJECTIVES 
• TO CREATE A SUCCESSFUL COMPANY IN 5-7 YEARS 
• TO MAKE AN OUTSTANDING RETURN ON INVESTMENT AND 
OF MEANINGFUL SIZE TO THE FUND 
• TO STRONGLY INFLUENCE THE COMPANY THROUGH THE BOARD: 
MANAGEMENT HIRING 
STRATEGY 
FINANCING 
• TO KEEP EQUITY INVESTMENT LOW ($5-lOM) AND TO EFFICIENTLY 
USE CAPITAL 
• INVEST IN STAGES TO HANDLE RISK 
------------------ COLUMBINE VENTURE FUNDS 
. ~ . 
7 
UNIVERSITY OBJECTIVES 
• TO CREATE VALUE FROM TECHNOLOGY 
• TO STIMULATE STUDENT INTEREST 
• TO SATISFY AND RETAIN FACULTY 
• TO GENERATE RESEARCH SUPPORT 
• TO AVOID CONFLICTS 
• TO FOSTER LOCAL ECONOMIC DEVELOPMENT 
------------------ COLUMBINE VENTURE FUNDS 
LESSONSLEARNED-1 
1. PROTECT THE PATENT POSITION 
PRIOR PUBLICATIONS CAN DESTROY IT 
2. DO NOT SELECT A CEO 
LET THE VENTURE CAPITALIST BUILD MANAGEMENT 
3. BE CAREFUL WHO YOU DEAL WITH 
------------------ COLUMBINE VENTURE FUNDS 
LESSONS LEARNED - 2 
• FEW OPPORTUNITIES HAVE START-UP POTENTIAL 
• FACULTY DOES NOT HAVE TO QUIT 
• THERE IS GOOD SCIENCE AT ALL UNNERSITIES 
• MICROANALYZE THE PATENT POSITION 
• INVOLVE THE UNIVERSITY - STOCK, RESEARCH, ETC. 
• GET A FOUNDING CEO INVOLVED EARLY 
• MARKET ISSUES ARE MOST COMMON REASONS FOR FAILURE 
• SET UP OFF-CAMPUS COMPANY OFFICES IMMEDIATELY 
• AVOID COMPLEX STRUCTURES 
• RETREAT GRACEFULLY 
------------------ COLUMBINE VENTURE FUNDS 
BENEFITS TO UNIVERSITY/FACULTY 
• VALUE OF STOCK MUCH GREATER THAN ROYALTIES 
• RESEARCH SUPPORT FROM START-UP 
• KEEPS TECHNOLOGY IN-STATE, BOOSTS ECONOMIC 
DEVELOPMENT AND GENERATES LOCAL JOBS 
• MORE SATISFYING TO FACULTY 
• HELPS ATTRACT AND RETAIN FACULTY 
• RETAINS MORE INFLUENCE ON TECHNOLOGY THAN IN A 
STRAIGHT LICENSE 
~~~~~~~~~~~~~~~~~~COLUMBINE VENTURE FUNDS 
SOME POTENTIAL PROBLEMS 
• LOSS OF FACULTY 
• CONFLICTS OF INTEREST 
• UNIVERSITY/FACULTY DO NOT UNDERSTAND STOCK OWNERSHIP 
AND INVESTMENT 
• LOSS OF CONTROL 
• REQUIRES POSTPONEMENT OF CASH ROYALTY INC011E FOR LESS 
CERTAIN STOCK VALUE IN FUTURE 
• CLASH OF BUSINESS AND ACADEMIC VALUES 
------------------ COLUMBINE VENTURE FUNDS 
If 
CONFLICTS OF INTEREST 
• USING PUBLIC FUNDS FOR PRIVATE GAIN 
• RESEARCH CONTRACTS VS ACADEMIC FREEDOM 
• FACULTY ALLOCATION OF TIME AND LOYALTY 
• HOW DO YOU EXPLAIN IT TO THOSE WHO DON'T 
PARTICIPATE OR BENEFIT? 
• HOW DOES THE UNIVERSITY SPLIT UP THE PIE? 
• WHO NEGOTIATES THE AGREEMENT? WHAT ARE SOUND POLICIES? 
• PECULIAR TO MEDICAL: CLINICAL TRIALS 
------------------ COLUMBINE VENTURE FUNDS 
; z_ 
/J 
VALUATION AND OWNERSHIP 
HOW TO VALUE TECHNOLOGY: 
• RESEARCH FUNDS EXPENDED TO DATE 
• STAGE OF DEVELOPMENT 
• SIZE OF ULTIMATE BUSINESS 
• CAPITAL NEEDED TO DEVELOP PRODUCTS 
• COMPETITIVE ALTERNATIVES(fHREATS 
• PROPRIETARY POSITION 
• OTHER INTERESTED PARTIES, A VALIDATION 
~~~~~~~~~~~~~~~~~~COLUMBINE VENTURE FUNDS 
SOME GUIDELINES 
• STOCK OWNERSHIP SUBSTITUTES FOR 
LUMP SUM CASH PAYMENTS 
• REASONABLE ROYALTY PAID WHEN SALES ARE MADE 
• LICENSE MUST BE EXCLUSIVE 
• MINIMUM ROYALTIES DUE WHEN SALES START 
• TECHNOLOGY REVERTS IF NOT COMMERCIALIZED 
DILIGENTLY 
• LOW OR NO OVERHEAD ON RESEARCH CONTRACTS 
PRINCIPLE: UNIVERSITY, FOUNDERS, VENTURE CAPITALISTS ARE IN 
PARTNERSHIP WHERE VALUE IS CREATED THROUGH INCREASES IN THE 
STOCK PRICE. NO ONE PARTY SHOULD EXTRACT INCOME BEFORE THE 
OTHERS. 
------------------ COLUMBINE VENTURE FUNDS 
·d I I 
SOME MYTHS 
• FACULTY MUST LEA VE UNIVERSITY TO START A COMPANY 
• START-UP CAPITAL IS SCARCE 
• ALL GOOD TECHNOLOGY IS ON THE COASTS 
• VENTURE CAPITALISTS GIVE RESEARCH GRANTS 
• THE BUSINESS PART IS EASY 
• A PROFESSOR CAN BE A CEO 
• STOCK IS OF NO VALUE 
• ROYALTIES MAXIMIZE INCOME 
--------....--..---------- COLUMBINE VENTURE FUNDS 
A GENERIC MODEL 
LICENSE TERMS: 
• EXCLUSIVE 
• NO LUMP SUM PAYMENTS 
• 3% NET SALES ROYALTY 
• $25K PER YEAR MINIMUM TO RETAIN EXCLUSIVITY 
COMMENCING ON SALES 
INITITAL STOCK OWNERSHIP: 
VENTURE CAPITALISTS -
RESERVED FOR MANAGEMENT -
UNNERSITY-
FACULTY-
50% - PREFERRED 
30%-COMMON 
5%-COMMON 
15%-COMMON 
------------------ COLUMBINE VENTURE FUNDS 
SEED FINANCING OF $100,000 
VALUATION OF $1,000,000 
FOUNDERS 
INVESTORS 
(SEED) 
OWNERSHIP 
(O/o) 
90 
10 
PRICE PER INVEST- FOUNDERS 
SHARE($) MENT ($) MULTIPLE 
0.05 45,000 20:1 
1.00 100,000 
-~l;l~?~~--.l!llIS21BB.ilE.![~~~1 
FIRST ROUND FINANCING OF $1,500,000 
VALUATION OF $3,500,000 
OWNERSHIP PRICE PER INVEST- FOUNDERS 
(Ofo) SHARE($) MENT ($) MULTIPLE 
FOUNDERS 51 0.05 45,000 40:1 
INVESTORS 
(SEED) 6 1.00 100,000 
INVESTORS 
(FIRST) 43 2.00 1,500,000 
~-- it111illillilEllllElfil 
I PUBLIC FINANCING OF $12,500,000 
I VALUATION OF $50,000,000 
! 
I 
I 
i 
i 
i 
I 
~ I FOUNDERS 
I 
OWNERSHIP PRICE PER 
(%} SHARE($} 
31 .05 
i i INVESTORS 
I (SEED) 3 1.00 
! 
i 
I
i INVESTORS 
(FIRST) 26 I 2.00 
I INVESTORS 
J I (INST.) 
PUBLIC 
15 7.00 
25 17.00 
INVEST-
MENT($} 
45,000 
100,000 
1,500,000 
3,000,000 
12,500,000 
FOUNDERS 
MULTIPLE 
340: 1 
;~~1ij~l1~iim:em:111a·11·sij~iJ~r 
SECOND ROUND FINANCING OF $3,000,000 
VALUATION OF $15,000,000 
OWNERSHIP PRICE PER INVEST- FOUNDERS 
(O/o) SHARE($) MENT ($) MULTIPLE 
FOUNDERS 41 0.05 45,000 140:1 
INVESTORS 
(SEED) 5 1.00 100,000 
INVESTORS 
(FIRST) 34 2.00 1,500,000 
INVESTORS 
(INST.) 20 7.00 3,000,000 
